Oncology-focused gene therapy player East Ocyon Bio raises $4.2 M led by Aeravti Ventures, Micro Lab
Gurugram-headquartered East Ocyon Bio , an allogeneic cell and gene therapy (CGT) startup, has closed its USD 4.2 million seed round led by Aeravti Ventures and Micro Labs. The newly raised funds will be used to enable several key initiatives like pre-clinical testing of CAR-NK and CAR-gamma delta T cell therapies, the creation of a GMP manufacturing facility, and Phase I clinical trials.East Ocyon Bio focuses on cell and gene therapies. The company claims that its proprietary technology uses natural killer (NK) cells to treat cancer.
Want to receive such news items in your inbox? Click Here to sign up for a trial.